About Omeros Corporation (NASDAQ:OMER)
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from its PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Pharmaceuticals
- Sector: Bio Therapeutic Drugs
- Symbol: NASDAQ:OMER
- CUSIP: 68214310
- Web: www.omeros.com
- Debt-to-Equity Ratio: 8.99%
- Current Ratio: 4.77%
- Quick Ratio: 4.74%
Sales & Book Value:
- Annual Sales: $41.62 million
- Price / Sales: 22.85
- Book Value: $0.19 per share
- Price / Book: 104.26
- Trailing EPS: ($1.29)
- Net Income: ($66,740,000.00)
- Net Margins: -88.42%
- Return on Assets: -42.19%
- Employees: 154
- Outstanding Shares: 48,000,000
Frequently Asked Questions for Omeros Corporation (NASDAQ:OMER)
What is Omeros Corporation's stock symbol?
Omeros Corporation trades on the NASDAQ under the ticker symbol "OMER."
How were Omeros Corporation's earnings last quarter?
Omeros Corporation (NASDAQ:OMER) posted its earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.18. The biopharmaceutical company had revenue of $21.66 million for the quarter, compared to analysts' expectations of $17.82 million. The company's revenue was up 91.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.34) earnings per share. View Omeros Corporation's Earnings History.
When will Omeros Corporation make its next earnings announcement?
Where is Omeros Corporation's stock going? Where will Omeros Corporation's stock price be in 2017?
8 brokerages have issued 1-year target prices for Omeros Corporation's shares. Their predictions range from $19.00 to $75.00. On average, they expect Omeros Corporation's stock price to reach $36.17 in the next twelve months. View Analyst Ratings for Omeros Corporation.
What are Wall Street analysts saying about Omeros Corporation stock?
Here are some recent quotes from research analysts about Omeros Corporation stock:
- 1. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (11/15/2017)
- 2. Maxim Group analysts commented, "Omeros announced that extended follow-up data from patients with immunoglobulin A (IgA) nephropathy treated with OMS721 were presented on November 4, 2017 at the American Society of Nephrology (ASN) Meeting in New Orleans. These data describe up to one-year follow-up of patients treated with OMS721 in the glomerulonephropathy Phase 2 clinical trial. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin- associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system." (11/6/2017)
- 3. Cantor Fitzgerald analysts commented, "Omeros announced that it received breakthrough therapy designation for its MASP-2 inhibitor, OMS721, for the treatment of IgA nephropathy (IgAN)." (6/13/2017)
- 4. Wedbush analysts commented, "The Wedbush View: With an emerging pipeline of rare disease focused products and OMIDRIA sales offsetting the company’s burn, we believe OMER to be an attractive investment for investors with a 2017-2018 horizon." (5/10/2017)
Who are some of Omeros Corporation's key competitors?
Some companies that are related to Omeros Corporation include AnaptysBio (ANAB), NovoCure Limited (NVCR), Acceleron Pharma (XLRN), Intercept Pharmaceuticals (ICPT), MyoKardia (MYOK), Ascendis Pharma A/S (ASND), Radius Health (RDUS), Clinigen Group PLC (CLIN), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), Ignyta (RXDX), Lexicon Pharmaceuticals (LXRX), Athenex (ATNX), Neuroderm Ltd (NDRM), Xencor (XNCR), Dermira (DERM), Amarin Corporation PLC (AMRN) and Flexion Therapeutics (FLXN).
Who are Omeros Corporation's key executives?
Omeros Corporation's management team includes the folowing people:
- Gregory A. Demopulos M.D., Chairman of the Board, President, Chief Executive Officer (Age 58)
- Michael A. Jacobsen, Chief Accounting Officer, Vice President - Finance, Treasurer (Age 58)
- Marcia S. Kelbon J.D., Vice President - Patent, General Counsel, Secretary (Age 57)
- Thomas J. Cable, Lead Independent Director (Age 77)
- Peter A. Demopulos M.D., Director (Age 61)
- Ray Aspiri, Independent Director (Age 78)
- Arnold C. Hanish, Independent Director (Age 69)
- Leroy E. Hood M.D., Ph.D., Independent Director (Age 78)
Who owns Omeros Corporation stock?
Omeros Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Ingalls & Snyder LLC (10.78%), Tocqueville Asset Management L.P. (1.00%), Stifel Financial Corp (0.82%), Bank of New York Mellon Corp (0.51%), Schwab Charles Investment Management Inc. (0.45%) and EAM Investors LLC (0.42%). Company insiders that own Omeros Corporation stock include Gregory A Md Demopulos, Marcia S Kelbon, Michael A Jacobsen and Thomas J Cable. View Institutional Ownership Trends for Omeros Corporation.
Who sold Omeros Corporation stock? Who is selling Omeros Corporation stock?
Omeros Corporation's stock was sold by a variety of institutional investors in the last quarter, including Stoneridge Investment Partners LLC and Russell Investments Group Ltd.. Company insiders that have sold Omeros Corporation company stock in the last year include Gregory A Md Demopulos, Michael A Jacobsen and Thomas J Cable. View Insider Buying and Selling for Omeros Corporation.
Who bought Omeros Corporation stock? Who is buying Omeros Corporation stock?
Omeros Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Chicago Equity Partners LLC, EAM Investors LLC, Stifel Financial Corp, Schwab Charles Investment Management Inc., Ingalls & Snyder LLC, AMP Capital Investors Ltd, Bank of New York Mellon Corp and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Omeros Corporation.
How do I buy Omeros Corporation stock?
Shares of Omeros Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Omeros Corporation's stock price today?
One share of Omeros Corporation stock can currently be purchased for approximately $19.81.
How big of a company is Omeros Corporation?
Omeros Corporation has a market capitalization of $957.68 million and generates $41.62 million in revenue each year. The biopharmaceutical company earns ($66,740,000.00) in net income (profit) each year or ($1.29) on an earnings per share basis. Omeros Corporation employs 154 workers across the globe.
How can I contact Omeros Corporation?
Omeros Corporation's mailing address is 201 Elliott Ave W, SEATTLE, WA 98119-4240, United States. The biopharmaceutical company can be reached via phone at +1-206-6765000.
MarketBeat Community Rating for Omeros Corporation (NASDAQ OMER)MarketBeat's community ratings are surveys of what our community members think about Omeros Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Omeros Corporation (NASDAQ:OMER) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 2 Hold Ratings, 5 Buy Ratings, 1 Strong Buy Rating|
|Consensus Rating:||Buy (Score: 2.88)|
|Consensus Price Target: ||$36.17 (82.57% upside)|
Consensus Price Target History for Omeros Corporation (NASDAQ:OMER)
Analysts' Ratings History for Omeros Corporation (NASDAQ:OMER)
(Data available from 11/18/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/8/2017||HC Wainwright||Initiated Coverage||Buy||$30.00||N/A|
|11/6/2017||Maxim Group||Reiterated Rating||Buy||$24.00||N/A|
|11/2/2017||Cowen and Company||Downgrade||Outperform -> Market Perform||N/A|
|8/24/2017||Cantor Fitzgerald||Reiterated Rating||Hold||$15.00 -> $19.00||High|
|6/14/2017||WBB Securities||Reiterated Rating||Strong-Buy||$75.00||High|
|4/1/2017||FBR & Co||Reiterated Rating||Buy||Low|
|3/17/2017||Needham & Company LLC||Reiterated Rating||Buy -> Buy||$24.00 -> $22.00||High|
|10/17/2016||S&P Equity Research||Boost Price Target||$7.65 -> $8.63||N/A|
Earnings History and Estimates Chart for Omeros Corporation (NASDAQ:OMER)
Earnings History by Quarter for Omeros Corporation (NASDAQ OMER)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/15/2018|| || || || || || || || |
|11/9/2017||Q3 2017||($0.34)||($0.16)||$17.82 million||$21.66 million||View||N/A|
|8/8/2017||Q2 2017||($0.35)||($0.23)||$14.63 million||$17.15 million||View||Listen|
|5/10/2017||Q1 2017||($0.35)||($0.34)||$13.32 million||$12.26 million||View||N/A|
|11/9/2016||Q3 2016||($0.40)||($0.34)||$11.64 million||$11.30 million||View||Listen|
|8/9/2016||Q216||($0.50)||($0.32)||$9.80 million||$10.00 million||View||Listen|
|5/10/2016||Q116||($0.43)||($0.54)||$8.79 million||$7.40 million||View||Listen|
|3/8/2016||Q415||($0.53)||($0.52)||$5.35 million||$6.66 million||View||Listen|
|11/9/2015||Q315||($0.47)||($0.46)||$7.97 million||$3.30 million||View||Listen|
|8/10/2015||Q215||($0.56)||($0.44)||$2.86 million||$3.20 million||View||Listen|
|5/11/2015||Q115||($0.63)||($0.51)||$0.15 million||$0.39 million||View||Listen|
|3/16/2015||Q4||($0.62)||($0.61)||$0.15 million||$0.18 million||View||Listen|
|11/10/2014||Q114||($0.59)||($0.54)||$0.43 million||$0.21 million||View||N/A|
|8/11/2014||Q2||($0.56)||($0.53)||$0.37 million||$0.45 million||View||N/A|
|5/12/2014||Q1||($0.45)||($0.45)||$0.45 million||$0.10 million||View||N/A|
|3/13/2014||Q413||($0.38)||($0.05)||$0.17 million||$1.70 million||View||N/A|
|11/7/2013||Q313||($0.44)||($0.46)||$0.14 million||$0.20 million||View||N/A|
|8/9/2013||Q213||($0.38)||($0.48)||$1.19 million||$0.14 million||View||N/A|
|5/10/2013||Q1 2013||($0.39)||($0.40)||$1.39 million||$1.10 million||View||N/A|
|3/18/2013||($0.35)||($0.30)||$1.49 million||$1.58 million||View||N/A|
|11/9/2012||Q312||($0.34)||($0.51)||$1.42 million||$1.40 million||View||N/A|
Earnings Estimates for Omeros Corporation (NASDAQ:OMER)
2017 EPS Consensus Estimate: ($1.12)
2018 EPS Consensus Estimate: $0.33
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Omeros Corporation (NASDAQ:OMER)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Omeros Corporation (NASDAQ OMER)
Insider Ownership Percentage: 12.10%
Institutional Ownership Percentage: 45.37%
Insider Trades by Quarter for Omeros Corporation (NASDAQ OMER)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/16/2017||Michael A Jacobsen||VP||Sell||12,000||$24.95||$299,400.00|| |
|6/15/2017||Michael A Jacobsen||VP||Sell||24,000||$21.20||$508,800.00|| |
|4/12/2017||Thomas J Cable||Director||Sell||3,000||$16.49||$49,470.00|| |
|12/7/2016||Gregory A Md Demopulos||CEO||Sell||306,124||$10.66||$3,263,281.84|| |
|12/6/2016||Gregory A Md Demopulos||CEO||Sell||102,040||$10.80||$1,102,032.00|| |
|12/5/2016||Gregory A Md Demopulos||CEO||Sell||102,040||$10.71||$1,092,848.40|| |
|12/2/2016||Gregory A Md Demopulos||CEO||Sell||306,120||$11.58||$3,544,869.60|| |
|9/15/2016||Marcia S Kelbon||VP||Sell||16,000||$10.91||$174,560.00|| |
|8/15/2016||Marcia S Kelbon||VP||Sell||15,900||$11.56||$183,804.00|| |
|7/15/2016||Marcia S Kelbon||VP||Sell||15,900||$11.50||$182,850.00|| |
|6/15/2016||Marcia S Kelbon||VP||Sell||15,900||$11.42||$181,578.00|| |
|5/16/2016||Marcia S Kelbon||VP||Sell||15,900||$9.94||$158,046.00|| |
|4/15/2016||Marcia S Kelbon||VP||Sell||15,900||$15.18||$241,362.00|| |
|3/24/2016||Thomas J Cable||Director||Sell||2,000||$14.81||$29,620.00|| |
|12/22/2015||Marcia S. Kelbon||VP||Sell||15,900||$15.00||$238,500.00|| |
|9/4/2015||Peter A Md Demopulos||Director||Buy||3,962||$12.68||$50,238.16|| |
|7/15/2015||Thomas J Cable||Director||Sell||2,000||$18.78||$37,560.00|| |
|3/24/2015||Thomas J Cable||Director||Sell||2,000||$24.50||$49,000.00|| |
|6/24/2014||Peter A Md Demopulos||Director||Buy||6,153||$16.20||$99,678.60|| |
|6/2/2014||Thomas J Cable||Director||Sell||5,000||$11.80||$59,000.00|| |
|7/3/2013||Thomas J Cable||Director||Sell||5,000||$5.21||$26,050.00|| |
|4/10/2013||Thomas J Cable||Director||Sell||5,000||$3.98||$19,900.00|| |
|1/4/2013||Ray Aspiri||Director||Buy||40,000||$5.72||$228,800.00|| |
|1/3/2013||Arnold C Hanish||Director||Buy||2,000||$5.58||$11,160.00|| |
Headline Trends for Omeros Corporation (NASDAQ:OMER)
Latest Headlines for Omeros Corporation (NASDAQ OMER)
Omeros Corporation (NASDAQ OMER) Chart for Saturday, November, 18, 2017